Mining & Metals
Arch Biopartners Hires US Bioengineering Lab to Advance Chronic Kidney Disease Program
Arch Biopartners (ARCH.V) has engaged a U.S.-based bioengineering laboratory to accelerate its chronic kidney disease program.Arch is developing drug candidates that target interluekin-32 (IL-32), which is implicated in diabetic kidney disease.The laboratory will perform studies to generate proprietary data and support Arch's patent portfolio covering its IL-32 drug candidates and related method-of-use claims.
$ARCH.V
